Search
Search Results
-
Imaging the fetal nonhuman primate brain with SV2A positron emission tomography (PET)
PurposeExploring synaptic density changes during brain growth is crucial to understanding brain development. Previous studies in nonhuman primates...
-
Imaging the effect of ketamine on synaptic density (SV2A) in the living brain
The discovery of ketamine as a rapid and robust antidepressant marks the beginning of a new era in the treatment of psychiatric disorders. Ketamine...
-
Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A
BackgroundAntiepileptic drugs, levetiracetam (LEV) and brivaracetam (BRV), bind to synaptic vesicle glycoprotein 2A (SV2A). In their anti-seizure...
-
Quantification of SV2A Binding in Rodent Brain Using [18F]SynVesT-1 and PET Imaging
PurposeSynapse loss is a hallmark of Alzheimer’s disease (AD) and correlates with cognitive decline. The validation of a noninvasive in vivo imaging...
-
The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study
Glutamatergic excitotoxicity is hypothesised to underlie synaptic loss in schizophrenia pathogenesis, but it is unknown whether synaptic markers are...
-
Assessment of cerebral drug occupancy in humans using a single PET-scan: A [11C]UCB-J PET study
PurposeHere, we evaluate a PET displacement model with a Single-step and Numerical solution in healthy individuals using the synaptic vesicle...
-
Evaluation of [11C]UCB-A positron emission tomography in human brains
BackgroundIn preclinical studies, the positron emission tomography (PET) imaging with [ 11 C]UCB-A provided promising results for imaging synaptic...
-
Integration of postmortem amygdala expression profiling, GWAS, and functional cell culture assays: neuroticism-associated synaptic vesicle glycoprotein 2A (SV2A) gene is regulated by miR-133a and miR-218
Recent genome-wide studies have begun to identify gene variants, expression profiles, and regulators associated with neuroticism, anxiety disorders,...
-
Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial
Selective serotonin reuptake inhibitors (SSRIs) are widely used for treating neuropsychiatric disorders. However, the exact mechanism of action and...
-
The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [11C]UCB-J
PurposeAging is a major societal concern due to age-related functional losses. Synapses are crucial components of neural circuits, and synaptic...
-
A systematic review and meta-analysis of neuroimaging studies examining synaptic density in individuals with psychotic spectrum disorders
BackgroundPsychotic disorders have long been considered neurodevelopmental disorders where excessive synaptic pruning and cortical volume loss are...
-
Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain
Psilocybin, a naturally occurring, tryptamine alkaloid prodrug, is currently being investigated for the treatment of a range of psychiatric...
-
Improved synthesis of SV2A targeting radiotracer [11C]UCB-J
Introduction[ 11 C]UCB-J is a tracer developed for PET (positron emission tomography) that has high affinity towards synaptic vesicle glycoprotein 2A...
-
Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy
One third of patients with epilepsy will continue to have uncontrolled seizures despite treatment with antiseizure medications (ASMs). There is...
-
Feasibility of imaging synaptic density in the human spinal cord using [11C]UCB-J PET
PurposeNeuronal damage and synapse loss in the spinal cord (SC) have been implicated in spinal cord injury (SCI) and neurodegenerative disorders such...
-
In vivo PET of synaptic density as potential diagnostic marker for cognitive disorders: prospective comparison with current imaging markers for neuronal dysfunction and relation to symptomatology - study protocol
Background18 F-FDG brain PET is clinically used for differential diagnosis in cognitive dysfunction of unclear etiology and for exclusion of a...
-
Neuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes
Over the last five decades, a large body of evidence has accrued for structural and metabolic brain alterations in schizophrenia. Here we provide an...
-
Adverse Event Profiles of Antiseizure Medications and the Impact of Coadministration on Drug Tolerability in Adults with Epilepsy
BackgroundAntiseizure medication (ASM) as monotherapy or in combination is the treatment of choice for most patients with epilepsy. Therefore,...
-
Synergistic effects of vagus nerve stimulation and antiseizure medication
IntroductionVagus nerve stimulation (VNS) is an effective, non-pharmacological therapy for epileptic seizures. Until now, favorable combinations of...
-
Exploring with [18F]UCB-H the in vivo Variations in SV2A Expression through the Kainic Acid Rat Model of Temporal Lobe Epilepsy
PurposeThe main purpose of this study was to understand how the positron emission tomography (PET) measure of the synaptic vesicle 2A (SV2A) protein...
